BCYC
Price
$8.66
Change
-$0.07 (-0.80%)
Updated
Apr 23, 04:59 PM (EDT)
Capitalization
519.71M
8 days until earnings call
INO
Price
$1.86
Change
+$0.02 (+1.08%)
Updated
Apr 23, 04:59 PM (EDT)
Capitalization
67.85M
Ad is loading...

BCYC vs INO

Header iconBCYC vs INO Comparison
Open Charts BCYC vs INOBanner chart's image
Bicycle Therapeutics
Price$8.66
Change-$0.07 (-0.80%)
Volume$6.75K
Capitalization519.71M
Inovio Pharmaceuticals
Price$1.86
Change+$0.02 (+1.08%)
Volume$4.83K
Capitalization67.85M
BCYC vs INO Comparison Chart
Loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
BCYC vs. INO commentary
Apr 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCYC is a Buy and INO is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 23, 2025
Stock price -- (BCYC: $8.73 vs. INO: $1.85)
Brand notoriety: BCYC: Not notable vs. INO: Notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: BCYC: 223% vs. INO: 70%
Market capitalization -- BCYC: $519.71M vs. INO: $67.85M
BCYC [@Biotechnology] is valued at $519.71M. INO’s [@Biotechnology] market capitalization is $67.85M. The market cap for tickers in the [@Biotechnology] industry ranges from $285.37B to $0. The average market capitalization across the [@Biotechnology] industry is $2.11B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BCYC’s FA Score shows that 1 FA rating(s) are green whileINO’s FA Score has 0 green FA rating(s).

  • BCYC’s FA Score: 1 green, 4 red.
  • INO’s FA Score: 0 green, 5 red.
According to our system of comparison, BCYC is a better buy in the long-term than INO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BCYC’s TA Score shows that 4 TA indicator(s) are bullish while INO’s TA Score has 5 bullish TA indicator(s).

  • BCYC’s TA Score: 4 bullish, 4 bearish.
  • INO’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, INO is a better buy in the short-term than BCYC.

Price Growth

BCYC (@Biotechnology) experienced а +12.07% price change this week, while INO (@Biotechnology) price change was +5.11% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.67%. For the same industry, the average monthly price growth was -9.26%, and the average quarterly price growth was -12.98%.

Reported Earning Dates

BCYC is expected to report earnings on Jul 31, 2025.

INO is expected to report earnings on May 08, 2024.

Industries' Descriptions

@Biotechnology (+7.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
BCYC($520M) has a higher market cap than INO($67.8M). INO YTD gains are higher at: 3.933 vs. BCYC (-37.643). INO has higher annual earnings (EBITDA): -109.89M vs. BCYC (-164.89M). BCYC has more cash in the bank: 880M vs. INO (84.8M). BCYC has less debt than INO: BCYC (9.49M) vs INO (12.4M). BCYC has higher revenues than INO: BCYC (35.3M) vs INO (203K).
BCYCINOBCYC / INO
Capitalization520M67.8M767%
EBITDA-164.89M-109.89M150%
Gain YTD-37.6433.933-957%
P/E RatioN/AN/A-
Revenue35.3M203K17,389%
Total Cash880M84.8M1,038%
Total Debt9.49M12.4M77%
FUNDAMENTALS RATINGS
BCYC vs INO: Fundamental Ratings
BCYC
INO
OUTLOOK RATING
1..100
217
VALUATION
overvalued / fair valued / undervalued
1..100
24
Undervalued
61
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8796
PRICE GROWTH RATING
1..100
9490
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BCYC's Valuation (24) in the null industry is somewhat better than the same rating for INO (61) in the Medical Specialties industry. This means that BCYC’s stock grew somewhat faster than INO’s over the last 12 months.

BCYC's Profit vs Risk Rating (100) in the null industry is in the same range as INO (100) in the Medical Specialties industry. This means that BCYC’s stock grew similarly to INO’s over the last 12 months.

BCYC's SMR Rating (87) in the null industry is in the same range as INO (96) in the Medical Specialties industry. This means that BCYC’s stock grew similarly to INO’s over the last 12 months.

INO's Price Growth Rating (90) in the Medical Specialties industry is in the same range as BCYC (94) in the null industry. This means that INO’s stock grew similarly to BCYC’s over the last 12 months.

INO's P/E Growth Rating (100) in the Medical Specialties industry is in the same range as BCYC (100) in the null industry. This means that INO’s stock grew similarly to BCYC’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BCYCINO
RSI
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
87%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
77%
MACD
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
75%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
75%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
88%
Advances
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
77%
Declines
ODDS (%)
Bearish Trend 7 days ago
86%
Bearish Trend 8 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
Bearish Trend 2 days ago
84%
Bearish Trend 2 days ago
84%
View a ticker or compare two or three
Ad is loading...
BCYC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
INO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CTAGX12.550.42
+3.46%
Calamos Timpani SMID Growth A
CSJIX65.401.27
+1.98%
Cohen & Steers Realty Shares I
STSAX5.94N/A
N/A
Allspring Common Stock C
HASGX11.66N/A
N/A
Harbor Small Cap Growth Instl
GVIYX10.90N/A
N/A
GuideStone Funds Value Equity Idx Instl

BCYC and

Correlation & Price change

A.I.dvisor indicates that over the last year, BCYC has been loosely correlated with INO. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if BCYC jumps, then INO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCYC
1D Price
Change %
BCYC100%
+16.24%
INO - BCYC
51%
Loosely correlated
+3.93%
RPTX - BCYC
49%
Loosely correlated
+14.17%
XNCR - BCYC
48%
Loosely correlated
+0.47%
RLAY - BCYC
48%
Loosely correlated
+6.55%
FHTX - BCYC
41%
Loosely correlated
+8.72%
More

INO and

Correlation & Price change

A.I.dvisor indicates that over the last year, INO has been loosely correlated with RPTX. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if INO jumps, then RPTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INO
1D Price
Change %
INO100%
+3.93%
RPTX - INO
56%
Loosely correlated
+14.17%
AXON - INO
53%
Loosely correlated
+2.51%
ARRY - INO
52%
Loosely correlated
+2.63%
ONCO - INO
50%
Loosely correlated
+9.39%
BCYC - INO
49%
Loosely correlated
+16.24%
More